# Epinephrine Inhalation Aerosol USP, a HFA-MDI Study for Assessment of Pharmacokinetics

> **NCT01188577** · PHASE1,PHASE2 · COMPLETED · sponsor: **Amphastar Pharmaceuticals, Inc.** · enrollment: 23 (actual)

## Conditions studied

- Asthma
- Bronchospasm
- Wheezing
- Shortness of Breath

## Interventions

- **DRUG:** Epinephrine Inhalation Aerosol, HFA
- **DRUG:** Epinephrine Inhalation Aerosol

## Key facts

- **NCT ID:** NCT01188577
- **Lead sponsor:** Amphastar Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-08
- **Primary completion:** 2010-09
- **Final completion:** 2011-01
- **Target enrollment:** 23 (ACTUAL)
- **Last updated:** 2017-07-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01188577

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01188577, "Epinephrine Inhalation Aerosol USP, a HFA-MDI Study for Assessment of Pharmacokinetics". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT01188577. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*